Exclusive Interview: Biopharma And A Biden Administration

An Interview With Greg Simon, Former Executive Director Of The Obama Administration’s Cancer Moonshot Initiative

A Biden administration, if elected, would protect biopharmaceutical innovation, tackle the rising costs of cancer drugs and “promote science, without politics.”

Voting booth with American flag
• Source: Shutterstock

The top two health care priorities for US presidential candidate and former Vice President Joe Biden, should he win the election, would be to implement a national COVID-19 plan, and to protect insurance coverage for Americans, said Greg Simon, a former Biden political aid. A “reinvigoration” of the Cancer Moonshot program, and dealing with drug pricing, could be next on Biden’s list. Simon spoke with In Vivo about his personal experiences; he is not officially part of Biden’s 2020 presidential campaign.

PDUFA And Gene Therapy: Bring ‘Fully Baked’ Ideas And ‘Don’t Be Stingy,’ Grogan Tells Developers

Former chief of White House Domestic Policy Council advises cell and gene therapy companies on strategies for promoting enhanced FDA review capabilities as part of Prescription Drug User Fee Act reauthorization negotiations.

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo